4Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis [ J ]. Gastroenterology, 1998, 115(1): 182-205.
5Larsen TB, Nielsen JN, Fredholm L, et al. Platelets and anticoagulantcapacity in patientswith inflammatory bowel disease [ J ]. Pathophysiol- Haemost Thromb, 2002, 32(2): 92-96.
6Kapsoritakis AN, Koukourakis MI, Sfiridak IA, et al. Mean platelet volume : a useful marker of inflamm atorybow eldisease activity [ J ]. Am J Gastroenterol, 2001,96(3) .. 76 -78.
7Souto JC, M artinez E, Roca M, et al. Prothrom botic state and signs of endothelial lesion in plasma of patients with inflamm atorybowel disease[J]. Dig Dis Sei, 1995, 40(9) : 1883 - 1889.
3Khan N,Abbas A M,Koleva Y N,et al.Long-term mesalamine maintenance in ulcerative colitis:which is more important adherence or daily dose[J].Inflamm Bowel Dis,2013,19(6):1123.
4Pant C,Anderson M P,Deshpande A,et al.Health care burden of clostridium difficile infection in hospitalized children with inflammatory bowel disease[J].Inflamm Bowel Dis,2013,19(5):1080.
6Khan N, Abbas AM, Koleva YN, et al. long- term mesalamine ma- intenance in ulcerative colitis:which is more important adherence or daily dose[J]. Intlamm Bowel Dis,2013,19(6) :1123 - 1129.
7Pant C, Anderson MP, Deshpande A, et al. health care burden of clostridium difficile infection in hospitalized children with inflam- matory bowel disease [ J ]. Inflamm Bowel Dis, 2013, 19 ( 5 ) : 1080 - 1085.
8Greenley RN, Kunz JH, Schurman JV, et al. Abdominal pain and health related quality of life in pediatric inflammatory bowel dis- ease[ J]. J Pediatr Psychol, 2013,38( 1 ) :63 -71.
